Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone
This article was originally published in Scrip
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
You may also be interested in...
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.
Merck & Co is discontinuing development of its adenosine A2a receptor antagonist, preladenant, for Parkinson's disease (PD) after an initial review of data from three separate Phase III trials failed to provide evidence of efficacy for the drug versus placebo.